USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
EP0101681B1
(en)
|
1981-09-08 |
1994-12-14 |
The Rockefeller University |
Antibody to a mediator activity composition and its use in a pharmaceutical composition
|
US4510245A
(en)
|
1982-11-18 |
1985-04-09 |
Chiron Corporation |
Adenovirus promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4704366A
(en)
|
1984-06-22 |
1987-11-03 |
Bio-Rad Laboratories, Inc. |
Process for binding IgG to protein A
|
US5672347A
(en)
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
DE3431140A1
(de)
|
1984-08-24 |
1986-03-06 |
Behringwerke Ag, 3550 Marburg |
Enhancer fuer eukaryotische expressionssysteme
|
IL73883A
(en)
|
1984-12-20 |
1990-12-23 |
Yeda Res & Dev |
Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
US5672502A
(en)
|
1985-06-28 |
1997-09-30 |
Celltech Therapeutics Limited |
Animal cell culture
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
ATE114673T1
(de)
|
1985-08-16 |
1994-12-15 |
Univ Rockefeller |
Modulator der anabolischen aktivität und seine verwendungen.
|
IT206190Z2
(it)
|
1985-12-17 |
1987-07-13 |
Iveco Fiat |
Perfezionamento alla carrozzeria di un autoveicolo pesante
|
US4968615A
(en)
|
1985-12-18 |
1990-11-06 |
Ciba-Geigy Corporation |
Deoxyribonucleic acid segment from a virus
|
US4925796A
(en)
|
1986-03-07 |
1990-05-15 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
US5681718A
(en)
|
1986-03-14 |
1997-10-28 |
Celltech Limited |
Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
DE3631229A1
(de)
|
1986-09-13 |
1988-03-24 |
Basf Ag |
Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
US5045468A
(en)
|
1986-12-12 |
1991-09-03 |
Cell Enterprises, Inc. |
Protein-free culture medium which promotes hybridoma growth
|
US4877608A
(en)
|
1987-11-09 |
1989-10-31 |
Rorer Pharmaceutical Corporation |
Pharmaceutical plasma protein formulations in low ionic strength media
|
US6238891B1
(en)
|
1987-11-18 |
2001-05-29 |
Cetus Oncology Corporation |
Method of increasing product expression through solute stress
|
US5118796A
(en)
|
1987-12-09 |
1992-06-02 |
Centocor, Incorporated |
Efficient large-scale purification of immunoglobulins and derivatives
|
AU626572B2
(en)
|
1988-07-18 |
1992-08-06 |
Chiron Corporation |
Monoclonal antibodies reactive with cachectin
|
AU632065B2
(en)
|
1988-09-23 |
1992-12-17 |
Novartis Vaccines And Diagnostics, Inc. |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
US6048728A
(en)
|
1988-09-23 |
2000-04-11 |
Chiron Corporation |
Cell culture medium for enhanced cell growth, culture longevity, and product expression
|
US5126250A
(en)
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
EP0366043B1
(en)
|
1988-10-24 |
1994-03-30 |
Otsuka Pharmaceutical Co., Ltd. |
Monoclonal antibody
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
ES2096553T3
(es)
|
1988-12-19 |
1997-03-16 |
American Cyanamid Co |
Metodo para el tratamiento de choque endotoxico en un animal mamifero.
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE4009603A1
(de)
|
1989-03-30 |
1990-10-04 |
Leybold Ag |
Vorrichtung zum ein- und ausschleusen eines werkstuecks in eine vakuumkammer
|
US4933435A
(en)
|
1989-04-05 |
1990-06-12 |
Bioprobe International |
Antibody purification process
|
US5169936A
(en)
|
1989-04-14 |
1992-12-08 |
Biogen, Inc. |
Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
|
EP0486526B2
(en)
|
1989-08-07 |
2001-03-07 |
Peptech Limited |
Tumour necrosis factor binding ligands
|
US5959087A
(en)
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
US6448380B2
(en)
|
1989-08-07 |
2002-09-10 |
Peptech Limited |
Tumor necrosis factor antibodies
|
GB8921123D0
(en)
|
1989-09-19 |
1989-11-08 |
Millar Ann B |
Treatment of ards
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5945098A
(en)
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
AU646695B2
(en)
|
1990-04-09 |
1994-03-03 |
Immunex Corporation |
Isolated viral protein cytokine antagonists
|
DE4037604A1
(de)
|
1990-04-25 |
1991-10-31 |
Bayer Ag |
Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
|
US5378612A
(en)
|
1990-05-11 |
1995-01-03 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Culture medium for production of recombinant protein
|
US5110913A
(en)
|
1990-05-25 |
1992-05-05 |
Miles Inc. |
Antibody purification method
|
US5096816A
(en)
|
1990-06-05 |
1992-03-17 |
Cetus Corporation |
In vitro management of ammonia's effect on glycosylation of cell products through pH control
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
GB9022545D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
GB9022547D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Purified immunoglobulin
|
GB9109645D0
(en)
|
1991-05-03 |
1991-06-26 |
Celltech Ltd |
Recombinant antibodies
|
GB2279077B
(en)
|
1990-12-21 |
1995-06-14 |
Celltech Ltd |
Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
|
US5994510A
(en)
|
1990-12-21 |
1999-11-30 |
Celltech Therapeutics Limited |
Recombinant antibodies specific for TNFα
|
GB9028123D0
(en)
|
1990-12-28 |
1991-02-13 |
Erba Carlo Spa |
Monoclonal antibodies against human tumor necrosis factor alpha
|
CA2288429C
(en)
|
1991-03-15 |
2006-04-25 |
Synergen, Inc. |
Pegylation of polypeptides
|
ES2289997T3
(es)
|
1991-03-18 |
2008-02-16 |
New York University |
Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
|
US20070298040A1
(en)
|
1991-03-18 |
2007-12-27 |
Centocor, Inc. |
Methods of treating seronegative arthropathy with anti-TNF antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US5698195A
(en)
|
1991-03-18 |
1997-12-16 |
New York University Medical Center |
Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
|
US20060246073A1
(en)
|
1991-03-18 |
2006-11-02 |
Knight David M |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US20040120952A1
(en)
|
2000-08-07 |
2004-06-24 |
Centocor, Inc |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US5656272A
(en)
|
1991-03-18 |
1997-08-12 |
New York University Medical Center |
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
|
US5328985A
(en)
|
1991-07-12 |
1994-07-12 |
The Regents Of The University Of California |
Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
|
JP3502093B2
(ja)
|
1991-07-15 |
2004-03-02 |
ザ・ウエルカム・ファウンデーション・リミテッド |
抗体の製造
|
DE69229477T2
(de)
|
1991-09-23 |
1999-12-09 |
Cambridge Antibody Tech |
Methoden zur Herstellung humanisierter Antikörper
|
GB9122820D0
(en)
|
1991-10-28 |
1991-12-11 |
Wellcome Found |
Stabilised antibodies
|
AU3244693A
(en)
|
1991-12-17 |
1993-07-19 |
Schering Corporation |
Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
|
WO1993019751A1
(en)
|
1992-04-02 |
1993-10-14 |
Smithkline Beecham Corporation |
Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
EP0585705B1
(en)
|
1992-08-28 |
1998-11-04 |
Bayer Corporation |
Use of monoclonal antibodies to TNF to treat bacterial meningitis
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
EP0663836B1
(en)
|
1992-10-08 |
1997-07-09 |
The Kennedy Institute Of Rheumatology |
Treatment of autoimmune and inflammatory disorders
|
JPH08509203A
(ja)
|
1992-10-15 |
1996-10-01 |
ダナ−ファーバー キャンサー インステテュート インコーポレイテッド |
TNF−α作用の拮抗剤を用いる肥満関連糖尿病▲II▼型のインスリン耐性の治療
|
JPH06292592A
(ja)
|
1993-02-09 |
1994-10-21 |
Snow Brand Milk Prod Co Ltd |
糖蛋白質の生産方法
|
EP0614984B2
(en)
|
1993-03-05 |
2010-11-03 |
Bayer HealthCare LLC |
Anti-TNF alpha human monoclonal antibodies
|
DE4307508A1
(de)
|
1993-03-10 |
1994-09-15 |
Knoll Ag |
Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
DE69432412T2
(de)
|
1993-05-12 |
2004-01-29 |
Xoma Corp |
Gelonin und einen antikörper entahltende immuntoxine
|
WO1994029347A1
(en)
|
1993-06-03 |
1994-12-22 |
Therapeutic Antibodies Inc. |
Antibody fragments in therapy
|
AU8083594A
(en)
|
1993-10-19 |
1995-05-08 |
Scripps Research Institute, The |
Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
|
EP0659766A1
(en)
|
1993-11-23 |
1995-06-28 |
Schering-Plough |
Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
|
NZ278607A
(en)
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
EP0666312A1
(en)
|
1994-02-08 |
1995-08-09 |
Wolfgang A. Renner |
Process for the improvement of mammalian cell growth
|
US5429746A
(en)
|
1994-02-22 |
1995-07-04 |
Smith Kline Beecham Corporation |
Antibody purification
|
EP0748338A4
(en)
|
1994-03-04 |
2001-03-28 |
Merck & Co Inc |
IN VITRO MATURATION OF ANTIBODIES BY MEANS OF ALANINE 'SCANNING' MUTAGENESIS
|
US5856179A
(en)
|
1994-03-10 |
1999-01-05 |
Genentech, Inc. |
Polypeptide production in animal cell culture
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
AU698393B2
(en)
|
1994-06-24 |
1998-10-29 |
Immunex Corporation |
Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
|
ZA955642B
(en)
|
1994-07-07 |
1997-05-06 |
Ortho Pharma Corp |
Lyophilized imaging agent formulation
|
US5561053A
(en)
|
1994-08-05 |
1996-10-01 |
Genentech, Inc. |
Method for selecting high-expressing host cells
|
SE503424C2
(sv)
|
1994-11-14 |
1996-06-10 |
Pharmacia Ab |
Process för rening av rekombinant koagulationsfaktor VIII
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
CA2761116A1
(en)
|
1995-04-27 |
1996-10-31 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
US6656466B1
(en)
|
1995-06-06 |
2003-12-02 |
Genetech, Inc. |
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
|
US5721121A
(en)
|
1995-06-06 |
1998-02-24 |
Genentech, Inc. |
Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
PT1516628E
(pt)
|
1995-07-27 |
2013-09-24 |
Genentech Inc |
Formulação de proteína liofilizada isotónica estável
|
JP4306813B2
(ja)
|
1995-09-19 |
2009-08-05 |
アスビオファーマ株式会社 |
動物細胞の新規培養方法
|
CN1173878A
(zh)
|
1995-10-16 |
1998-02-18 |
尤尼利弗公司 |
双功能或双价抗体片段类似物
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
AR005035A1
(es)
|
1995-12-11 |
1999-04-07 |
Merck Patent Ges Mit Beschränkter Haftung |
Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
|
HU228630B1
(en)
|
1996-02-09 |
2013-04-29 |
Abbott Biotech Ltd |
Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
|
EP0802257B1
(fr)
|
1996-04-19 |
2002-08-21 |
Societe Des Produits Nestle S.A. |
Lignée immortalisée de cellules épithéliales du colon humain
|
TW491855B
(en)
|
1996-08-07 |
2002-06-21 |
Csl Ltd |
Purification of immunoglobulins
|
EP2243827B2
(en)
|
1996-08-30 |
2017-11-22 |
Life Technologies Corporation |
Serum-free mammalian cell culture medium, and uses thereof
|
US20040171152A1
(en)
|
1996-10-10 |
2004-09-02 |
Invitrogen Corporation |
Animal cell culture media comprising non-animal or plant-derived nutrients
|
DE69739673D1
(de)
|
1996-11-27 |
2009-12-31 |
Genentech Inc |
Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
|
KR20080059467A
(ko)
|
1996-12-03 |
2008-06-27 |
아브게닉스, 인크. |
복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
|
GB9625175D0
(en)
|
1996-12-04 |
1997-01-22 |
Medi Cult As |
Serum-free cell culture media
|
US5804420A
(en)
|
1997-04-18 |
1998-09-08 |
Bayer Corporation |
Preparation of recombinant Factor VIII in a protein free medium
|
KR100564189B1
(ko)
|
1997-04-28 |
2006-03-27 |
일라이 릴리 앤드 캄파니 |
활성화 프로틴c의 가공을 위한 개선된 방법
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
WO1998056418A1
(en)
|
1997-06-13 |
1998-12-17 |
Genentech, Inc. |
Stabilized antibody formulation
|
US6475725B1
(en)
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
US20040191256A1
(en)
|
1997-06-24 |
2004-09-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
DE69830315T2
(de)
|
1997-06-24 |
2006-02-02 |
Genentech Inc., San Francisco |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
US20040136986A1
(en)
|
1997-10-31 |
2004-07-15 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US20020045207A1
(en)
|
1997-10-31 |
2002-04-18 |
Lynne A. Krummen |
Glycoprotein production process
|
EP1028751B1
(en)
|
1997-10-31 |
2008-12-31 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
WO1999028455A1
(de)
|
1997-12-03 |
1999-06-10 |
Roche Diagnostics Gmbh |
Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
|
WO1999032605A1
(en)
|
1997-12-19 |
1999-07-01 |
Novo Nordisk A/S |
Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
|
ES2340112T3
(es)
|
1998-04-20 |
2010-05-28 |
Glycart Biotechnology Ag |
Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
|
WO1999057246A1
(en)
|
1998-05-01 |
1999-11-11 |
Life Technologies, Inc. |
Animal cell culture media comprising non-animal or plant-derived nutrients
|
DK1308455T3
(da)
|
1998-05-06 |
2006-07-31 |
Genentech Inc |
Sammensætning omfattende anti-HER2-antistoffer
|
CN103641885A
(zh)
|
1998-05-06 |
2014-03-19 |
基因技术股份有限公司 |
用离子交换层析纯化蛋白质
|
DE19821933C1
(de)
|
1998-05-15 |
1999-11-11 |
Disetronic Licensing Ag |
Vorrichtung zur Verabreichung eines injizierbaren Produkts
|
DE19822031C2
(de)
|
1998-05-15 |
2000-03-23 |
Disetronic Licensing Ag |
Autoinjektionsgerät
|
US6528286B1
(en)
|
1998-05-29 |
2003-03-04 |
Genentech, Inc. |
Mammalian cell culture process for producing glycoproteins
|
US6406909B1
(en)
|
1998-07-10 |
2002-06-18 |
Chugai Seiyaku Kabushiki Kaisha |
Serum-free medium for culturing animal cells
|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
AU3633000A
(en)
|
1999-03-26 |
2000-10-16 |
Human Genome Sciences, Inc. |
Neutrokine-alpha binding proteins and methods based thereon
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
US6506598B1
(en)
|
1999-04-26 |
2003-01-14 |
Genentech, Inc. |
Cell culture process
|
WO2000066160A1
(fr)
|
1999-04-28 |
2000-11-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
|
AT409379B
(de)
|
1999-06-02 |
2002-07-25 |
Baxter Ag |
Medium zur protein- und serumfreien kultivierung von zellen
|
DE60028210T2
(de)
|
1999-07-30 |
2007-03-08 |
Genentech, Inc., South San Francisco |
Geladene filtrationmembranen und deren verwendungen
|
DE60044690D1
(de)
|
1999-09-27 |
2010-08-26 |
Genentech Inc |
Verfahren zur Herstellung von rekombinanten Proteinen mittels Inhibitoren von Apoptose
|
AR026743A1
(es)
|
1999-12-09 |
2003-02-26 |
Pharmacia Ab |
Produccion de peptidos
|
KR20010056451A
(ko)
|
1999-12-15 |
2001-07-04 |
윤재승 |
아르기닌이 강화된 동물세포 배양용 배지 조성물
|
JP4516711B2
(ja)
|
1999-12-28 |
2010-08-04 |
中外製薬株式会社 |
安定な抗体組成物及び注射製剤
|
DE60120356T2
(de)
|
2000-02-08 |
2007-06-14 |
Genentech, Inc., South San Francisco |
Verbesserte galactosylierung von rekombinanten proteinen
|
WO2001058956A2
(en)
|
2000-02-10 |
2001-08-16 |
Abbott Laboratories |
Antibodies that bind human interleukin-18 and methods of making and using
|
GB0003231D0
(en)
|
2000-02-11 |
2000-04-05 |
Medi Cult As |
Cell culture media
|
JP2001218840A
(ja)
|
2000-02-14 |
2001-08-14 |
Kanegafuchi Chem Ind Co Ltd |
トランスフォーミング増殖因子βの吸着材、吸着除去方法および吸着器
|
WO2001077362A1
(fr)
|
2000-04-06 |
2001-10-18 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage immunologique d'anticorps anti hm1 . 24
|
CA2747325A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US7598055B2
(en)
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
EP2322644A1
(en)
|
2000-06-28 |
2011-05-18 |
GlycoFi, Inc. |
Methods for producing modified glycoproteins
|
EP1298217A4
(en)
|
2000-07-05 |
2004-09-08 |
Mitsubishi Pharma Corp |
GLYCOPROTEIN PRODUCTION PROCESS
|
JP5490972B2
(ja)
|
2000-08-04 |
2014-05-14 |
中外製薬株式会社 |
タンパク質注射製剤
|
US20050249735A1
(en)
|
2000-08-07 |
2005-11-10 |
Centocor, Inc. |
Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US20060018907A1
(en)
|
2000-08-07 |
2006-01-26 |
Centocor, Inc. |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
WO2002016590A2
(en)
|
2000-08-21 |
2002-02-28 |
Clonex Development, Inc. |
Methods and compositions for increasing protein yield from a cell culture
|
HUP0301245A3
(en)
|
2000-10-02 |
2005-12-28 |
Novo Nordisk Healthcare Ag |
Tmethod for the production of vitamin k-dependent proteins
|
US20090151023A1
(en)
|
2000-11-13 |
2009-06-11 |
Viktor Kuvshinov |
Transformation system for Camelina sativa
|
DE60230858D1
(de)
|
2001-02-15 |
2009-03-05 |
Centocor Inc |
Chemisch definiertes medium für kultivierte säugerzellen
|
US20030096414A1
(en)
|
2001-03-27 |
2003-05-22 |
Invitrogen Corporation |
Culture medium for cell growth and transfection
|
AU2002256005A1
(en)
|
2001-03-27 |
2002-10-08 |
Smithkline Beecham Corporation |
Control of glycoforms in igg
|
AU2002311976A1
(en)
|
2001-05-24 |
2002-12-03 |
Human Genome Sciences, Inc. |
Antibodies against tumor necrosis factor delta (april)
|
US20030012786A1
(en)
|
2001-05-25 |
2003-01-16 |
Teoh Leah S. |
Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
AU2002316230A1
(en)
|
2001-06-13 |
2002-12-23 |
Genentech, Inc. |
Methods of culturing animal cells and polypeptide production in animal cells
|
TR201809008T4
(tr)
|
2001-06-26 |
2018-07-23 |
Amgen Fremont Inc |
Opgl ye karşi antikorlar.
|
EP2180044A1
(en)
|
2001-08-03 |
2010-04-28 |
GlycArt Biotechnology AG |
Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
|
GB0119520D0
(en)
|
2001-08-10 |
2001-10-03 |
Owen Mumford Ltd |
Improvements relating to injection devices
|
JP4351049B2
(ja)
|
2001-10-02 |
2009-10-28 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
真核細胞中で組換えタンパク質を生産する方法
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
WO2003035835A2
(en)
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Glycoprotein compositions
|
AU2002340787B2
(en)
|
2001-11-12 |
2009-09-17 |
Monash University |
Peptide purification by means of metal ion affinity chromatography
|
PL370550A1
(en)
|
2001-11-28 |
2005-05-30 |
Sandoz Ag |
Method for producing a recombinant polypeptide
|
CA2466881A1
(en)
|
2001-11-28 |
2003-06-05 |
Sandoz Gmbh |
Cell culture process
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
WO2003046162A2
(en)
|
2001-11-28 |
2003-06-05 |
Polymun Scientific Immunbiologische Forschung Gmbh |
Process for the production of polypeptides in mammalian cell cultures
|
DE60231651D1
(de)
|
2001-12-21 |
2009-04-30 |
Immunex Corp |
Proteinreinigungsverfahren
|
AU2003210802B2
(en)
|
2002-02-05 |
2009-09-10 |
Genentech Inc. |
Protein purification
|
US20030161828A1
(en)
|
2002-02-19 |
2003-08-28 |
Abbott Gmbh & Co. Kg |
Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
|
CA2417689C
(en)
|
2002-03-05 |
2006-05-09 |
F. Hoffmann-La Roche Ag |
Improved methods for growing mammalian cells in vitro
|
JP2005521401A
(ja)
|
2002-03-27 |
2005-07-21 |
イミュネックス・コーポレーション |
ポリペプチド産生を増加させる方法
|
US20030190710A1
(en)
|
2002-03-28 |
2003-10-09 |
Devries Ruth L. |
Control of glycoforms in IgG
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20060234226A1
(en)
|
2002-04-26 |
2006-10-19 |
Fahner Robert L |
Non-affinity purification of proteins
|
US20040009172A1
(en)
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20040029229A1
(en)
|
2002-05-20 |
2004-02-12 |
Reeves Philip J. |
High level protein expression system
|
MXPA05000552A
(es)
|
2002-07-15 |
2005-04-28 |
Immunex Corp |
Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
|
US20070202104A1
(en)
|
2002-07-19 |
2007-08-30 |
Abbott Laboratories S.A. |
Treatment of spondyloarthropathies using TNFalpha inhibitors
|
US20090280065A1
(en)
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
US6974681B1
(en)
|
2002-08-23 |
2005-12-13 |
Immunex Corporation |
Cell culture performance with vanadate
|
US6924124B1
(en)
|
2002-08-23 |
2005-08-02 |
Immunex Corporation |
Feeding strategies for cell culture
|
US7067279B1
(en)
|
2002-08-23 |
2006-06-27 |
Immunex Corporation |
Cell culture performance with betaine
|
EP1578774B1
(en)
|
2002-09-18 |
2013-11-06 |
Danisco US Inc. |
Purification of immunoglobulins
|
US6890736B1
(en)
|
2002-09-20 |
2005-05-10 |
Immunex Corporation |
Methods for producing proteins in cultured cells
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
CA2504134C
(en)
|
2002-11-01 |
2012-03-06 |
Bayer Healthcare Llc |
Process for concentration of macromolecules
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
US20040162414A1
(en)
|
2002-11-22 |
2004-08-19 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
US20040101939A1
(en)
|
2002-11-22 |
2004-05-27 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
WO2004055164A2
(en)
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
PL377731A1
(pl)
|
2002-12-23 |
2006-02-06 |
Bristol-Myers Squibb Company |
Sposoby hodowli komórek ssaczych do wytwarzania białka
|
JP4496086B2
(ja)
|
2002-12-23 |
2010-07-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
タンパク質製造のための哺乳類細胞培養方法を用いる生成物品質の増大
|
WO2004076485A1
(en)
|
2003-02-28 |
2004-09-10 |
Lonza Biologics Plc. |
Antibody purification by protein a and ion exchange chromatography
|
CN100432217C
(zh)
|
2003-05-01 |
2008-11-12 |
帝斯曼知识产权资产管理有限公司 |
通过对悬浮的动物细胞进行灌流式培养来生产生物物质的方法
|
SI1623019T1
(sl)
|
2003-05-15 |
2010-10-29 |
Wyeth Llc |
Omejeno glukozno dovajanje za živalsko celično kulturo
|
GB2404665B
(en)
|
2003-08-08 |
2005-07-06 |
Cambridge Antibody Tech |
Cell culture
|
ES2565077T3
(es)
|
2003-10-10 |
2016-03-31 |
Novo Nordisk Health Care Ag |
Método para producción en gran escala de un polipéptido en células eucariotas
|
FR2861080B1
(fr)
|
2003-10-20 |
2006-02-17 |
Lab Francais Du Fractionnement |
Anticorps presentant un taux de fucose et de galactose optimise
|
WO2005042569A1
(en)
|
2003-10-24 |
2005-05-12 |
Amgen, Inc. |
Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
DE10355251A1
(de)
|
2003-11-26 |
2005-06-23 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
|
CA2548808C
(en)
|
2003-12-08 |
2015-07-07 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind or neutralize dengue virus
|
LT2805728T
(lt)
|
2003-12-23 |
2020-05-25 |
Genentech, Inc. |
Nauji anti-il 13 antikūnai ir jų naudojimai
|
EP1697414A2
(en)
|
2003-12-23 |
2006-09-06 |
Applied Research Systems ARS Holding N.V. |
Process for the production of tumor necrosis factor-binding proteins
|
US20080058507A1
(en)
|
2004-02-11 |
2008-03-06 |
Hui Liu |
Method For The Removal Of Aggregate Proteins From Recombinant Samples Using Ion Exchange Chromatography
|
AU2005211890B2
(en)
|
2004-02-12 |
2011-07-28 |
Merck Patent Gmbh |
Highly concentrated liquid formulations of anti-EGFR antibodies
|
CA2552639C
(en)
|
2004-02-27 |
2012-05-01 |
Ge Healthcare Bio-Sciences Ab |
A process for the purification of antibodies
|
CN1234725C
(zh)
|
2004-04-07 |
2006-01-04 |
陈志南 |
一种高效快速纯化制备片段抗体的方法
|
TW201705980A
(zh)
|
2004-04-09 |
2017-02-16 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
US20060127950A1
(en)
|
2004-04-15 |
2006-06-15 |
Massachusetts Institute Of Technology |
Methods and products related to the improved analysis of carbohydrates
|
US20060057638A1
(en)
|
2004-04-15 |
2006-03-16 |
Massachusetts Institute Of Technology |
Methods and products related to the improved analysis of carbohydrates
|
CA2562772A1
(en)
|
2004-04-15 |
2005-10-27 |
Glycofi, Inc. |
Production of galactosylated glycoproteins in lower eukaryotes
|
RU2006138181A
(ru)
|
2004-05-04 |
2008-06-10 |
Ново Нордиск Хелс Кеа Аг (Ch) |
О-связанные гликоформы полипептидов и способ их изготовления
|
AU2005269763A1
(en)
|
2004-07-21 |
2006-02-09 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform
|
US20060223147A1
(en)
|
2004-08-05 |
2006-10-05 |
Kyowa Hakko Kogyo Co., Ltd., |
Process for producing glycoprotein composition
|
US7294484B2
(en)
|
2004-08-27 |
2007-11-13 |
Wyeth Research Ireland Limited |
Production of polypeptides
|
US9045725B2
(en)
|
2004-09-30 |
2015-06-02 |
Bayer Healthcare Llc |
Devices and methods for integrated continuous manufacturing of biological molecules
|
EP1807111A4
(en)
|
2004-10-08 |
2009-05-27 |
Abbott Biotech Ltd |
SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
|
US20060194301A1
(en)
|
2004-10-09 |
2006-08-31 |
Doctor Bhupendra P |
Large-scale production of human serum butyrylcholinesterase as a bioscavenger
|
RU2389552C2
(ru)
|
2004-10-21 |
2010-05-20 |
Джи-И Хелткер Байо-Сайенсиз АБ |
Способ очистки антител
|
US20060094104A1
(en)
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
US20080160577A1
(en)
|
2005-02-04 |
2008-07-03 |
Glaxo Group Limited |
Optimization of Heterologous Polypeptide Expression
|
WO2006084826A1
(en)
|
2005-02-11 |
2006-08-17 |
Novo Nordisk Health Care Ag |
Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
|
PL1869065T3
(pl)
|
2005-03-11 |
2020-09-21 |
Wyeth Llc |
Sposób prowadzenia chromatografii podziałowej ze słabym wiązaniem
|
WO2006107990A2
(en)
|
2005-04-05 |
2006-10-12 |
The Johns Hopkins University |
Improving protein n-glycosylation of eukaryotic cells using dolichol-linked oligosaccharide synthesis pathway, other n-gylosylation-increasing methods, and engineered hosts expressing products with increased n-glycosylation
|
WO2006110277A1
(en)
|
2005-04-11 |
2006-10-19 |
Medarex, Inc. |
Protein purification using hcic amd ion exchange chromatography
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US20090203055A1
(en)
|
2005-04-18 |
2009-08-13 |
Massachusetts Institute Of Technology |
Compositions and methods for RNA interference with sialidase expression and uses thereof
|
WO2006113666A2
(en)
|
2005-04-19 |
2006-10-26 |
Massachusetts Institute Of Technology |
Amphiphilic polymers and methods of use thereof
|
NZ608319A
(en)
|
2005-05-16 |
2014-08-29 |
Abbvie Biotechnology Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
US20060275867A1
(en)
|
2005-06-03 |
2006-12-07 |
Veronique Chotteau |
Process
|
AU2006255085A1
(en)
|
2005-06-03 |
2006-12-14 |
Genentech, Inc. |
Method of producing antibodies with modified fucosylation level
|
CN101506238B
(zh)
|
2005-06-30 |
2013-11-06 |
森托科尔公司 |
具有提高治疗活性的方法和成分
|
KR101419729B1
(ko)
|
2005-07-26 |
2014-07-17 |
상가모 바이오사이언스 인코포레이티드 |
외래 핵산 서열의 표적화된 통합 및 발현
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
WO2007024743A2
(en)
|
2005-08-19 |
2007-03-01 |
Centocor, Inc. |
Proteolysis resistant antibody preparations
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
US20080219952A1
(en)
|
2005-08-26 |
2008-09-11 |
Ares Trading S.A. |
Process For the Preparation of Glycosylated Interferon Beta
|
WO2007028144A2
(en)
|
2005-09-02 |
2007-03-08 |
Glycofi, Inc |
Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
|
AR058140A1
(es)
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
AU2006337105B2
(en)
|
2005-11-01 |
2013-05-02 |
Abbvie Biotechnology Ltd |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
US8470318B2
(en)
|
2005-11-07 |
2013-06-25 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
EP1957099B1
(en)
|
2005-11-07 |
2015-03-25 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
US20080206246A1
(en)
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
SI1957630T2
(sl)
|
2005-12-08 |
2023-07-31 |
Amgen Inc. |
Izboljšana proizvodnja glikoproteinov z uporabo mangana
|
EP1974014B1
(en)
|
2006-01-04 |
2017-04-19 |
Baxalta Incorporated |
Oligopeptide-free cell culture media
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
US20070202051A1
(en)
|
2006-02-10 |
2007-08-30 |
Pari Gmbh |
Aerosols for sinunasal drug delivery
|
NZ572379A
(en)
|
2006-04-05 |
2012-06-29 |
Univ Rockefeller |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
EP3088410A3
(en)
|
2006-04-05 |
2016-12-28 |
AbbVie Biotechnology Ltd |
Antibody purification
|
EP2010214A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
EP2012586A4
(en)
|
2006-04-10 |
2010-08-18 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
|
US20080118496A1
(en)
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
US20090317399A1
(en)
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
US20080131374A1
(en)
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
MX2008014744A
(es)
|
2006-05-19 |
2009-02-10 |
Glycofi Inc |
Composiciones de eritrocpoyetina.
|
US20100021451A1
(en)
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
US20080311043A1
(en)
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
WO2009017491A1
(en)
|
2006-06-14 |
2009-02-05 |
Smithkline Beecham Corporation |
Methods for purifying antibodies using ceramic hydroxyapatite
|
NZ572765A
(en)
|
2006-06-30 |
2012-08-31 |
Abbott Biotech Ltd |
Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
|
US8129145B2
(en)
|
2006-07-13 |
2012-03-06 |
Wyeth Llc |
Production of glycoproteins
|
US9766217B2
(en)
|
2006-09-08 |
2017-09-19 |
Novo Nordisk A/S |
Methods of optimizing chromatographic separation of polypeptides
|
CN103436574B
(zh)
|
2006-09-10 |
2016-08-10 |
葛莱高托普有限公司 |
骨髓白血病来源的细胞在抗体表达中的用途
|
MX346523B
(es)
*
|
2006-09-13 |
2017-03-23 |
Abbvie Inc |
Mejoras de cultivos celulares.
|
EP2500415A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
US10982250B2
(en)
|
2006-09-18 |
2021-04-20 |
Genentech, Inc. |
Methods of protein production
|
AU2007307107B2
(en)
|
2006-10-06 |
2011-11-03 |
Amgen Inc. |
Stable antibody formulations
|
NZ597676A
(en)
|
2006-10-27 |
2013-07-26 |
Abbvie Biotechnology Ltd |
Crystalline anti-hTNFalpha antibodies
|
AU2007317755A1
(en)
|
2006-10-27 |
2008-05-15 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
WO2008055260A2
(en)
|
2006-11-03 |
2008-05-08 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
WO2008068879A1
(en)
|
2006-12-06 |
2008-06-12 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human erythropoietin
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
CA2672979A1
(en)
|
2006-12-22 |
2008-07-03 |
F. Hoffmann-La Roche Ag |
Selection method
|
WO2008083150A2
(en)
|
2006-12-28 |
2008-07-10 |
Centocor Ortho Biotech Inc. |
Methods and vectors for generating asialylated immunoglobulins
|
US7691980B2
(en)
|
2007-01-09 |
2010-04-06 |
Bio-Rad Laboratories, Inc. |
Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
|
JP2010516651A
(ja)
|
2007-01-17 |
2010-05-20 |
メルク セローノ ソシエテ アノニム |
Fc含有タンパク質の精製のための方法
|
EP2115126B1
(en)
|
2007-03-02 |
2015-04-08 |
Wyeth LLC |
Use of copper and glutamate in cell culture for production of polypeptides
|
NZ598881A
(en)
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
CA2682170A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
CA2682578C
(en)
|
2007-04-03 |
2015-05-26 |
Oxyrane Uk Limited |
Glycosylation of molecules
|
US20110213137A1
(en)
|
2007-04-16 |
2011-09-01 |
Momenta Pharmaceuticals, Inc. |
Isotopically-labeled glycans
|
EP2135093B1
(en)
|
2007-04-16 |
2015-04-15 |
Momenta Pharmaceuticals, Inc. |
Analysis of phosphorylated glycans, glcopeptides or glycoproteins by imac
|
EP2135089B1
(en)
|
2007-04-16 |
2015-09-02 |
Momenta Pharmaceuticals, Inc. |
Comparative analysis of protein conformations by using 2d noesy nmr spectra
|
AU2008240071A1
(en)
|
2007-04-16 |
2008-10-23 |
Momenta Pharmaceuticals, Inc. |
Characterization of N-glycan mixtures by nuclear magnetic resonance
|
CA2682735C
(en)
|
2007-04-16 |
2015-06-23 |
Momenta Pharmaceuticals, Inc. |
Multi-dimensional chromatographic methods for separating n-glycans
|
US20120264927A1
(en)
|
2007-04-16 |
2012-10-18 |
Ian Christopher Parsons |
Methods for labeling glycans
|
EP2135090A1
(en)
|
2007-04-16 |
2009-12-23 |
Momenta Pharmaceuticals, Inc. |
Proteolytic release of glycans
|
CA2682695A1
(en)
|
2007-04-16 |
2008-10-30 |
Momenta Pharmaceuticals, Inc. |
Characterization of n-glycans using exoglycosidases
|
WO2008128230A1
(en)
|
2007-04-16 |
2008-10-23 |
Momenta Pharmaceuticals, Inc. |
Reference glycoprotein products and related methods
|
BRPI0810472A2
(pt)
|
2007-04-16 |
2014-11-11 |
Momenta Pharmaceuticals Inc |
Métodos relacionados à glicosilação da superfície celular
|
EP2135091B1
(en)
|
2007-04-16 |
2011-06-08 |
Momenta Pharmaceuticals, Inc. |
Ms methods to evaluate glycans
|
PT2137655E
(pt)
|
2007-04-16 |
2012-09-14 |
Momenta Pharmaceuticals Inc |
Produtos de glicoproteína definidos e métodos relacionados
|
TW200902708A
(en)
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
WO2008135498A2
(en)
|
2007-05-04 |
2008-11-13 |
Novo Nordisk A/S |
Prevention of protein degradation in mammalian cell cultures
|
CA2687082C
(en)
|
2007-05-11 |
2014-01-14 |
Amgen Inc. |
Improved feed media
|
WO2008150491A2
(en)
|
2007-05-31 |
2008-12-11 |
Abbott Laboratories |
BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
|
WO2008150490A2
(en)
|
2007-06-01 |
2008-12-11 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriasis and crohn's disease
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
US20100221823A1
(en)
|
2007-06-11 |
2010-09-02 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
ES2751022T3
(es)
|
2007-07-09 |
2020-03-30 |
Genentech Inc |
Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos
|
EP2173380A4
(en)
|
2007-07-13 |
2011-08-31 |
Abbott Biotech Ltd |
METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER
|
KR100897159B1
(ko)
|
2007-07-26 |
2009-05-14 |
보령제약 주식회사 |
식물 유래의 재조합 인간 CTLA4Ig 융합단백질 및이의 생산 방법
|
RU2010107994A
(ru)
|
2007-08-08 |
2011-09-20 |
Эбботт Лэборетриз (Us) |
Композиции и способы кристаллизации антител
|
ES2657055T3
(es)
|
2007-08-09 |
2018-03-01 |
Wyeth Llc |
Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
|
CN101802005B
(zh)
|
2007-08-28 |
2015-09-16 |
艾伯维生物技术有限公司 |
包括关于阿达木单抗的结合蛋白质的组合物和方法
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
US20110117601A1
(en)
|
2007-08-31 |
2011-05-19 |
Markus Haberger |
Glycosylation Profile Analysis
|
DK2195444T3
(en)
|
2007-10-12 |
2015-08-24 |
Sigma Aldrich Co Llc |
Cell line and methods for enhanced sialylation of glycoprotein.
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
WO2009058307A1
(en)
|
2007-10-29 |
2009-05-07 |
University Of Georgia Research Foundation, Inc. |
In vivo isotopic labeling method for quantitative glycomics
|
WO2009058769A1
(en)
|
2007-10-30 |
2009-05-07 |
Schering Corporation |
Purification of antibodies containing hydrophobic variants
|
US20130195888A1
(en)
|
2007-11-30 |
2013-08-01 |
Abbvie |
Ultrafiltration and diafiltration formulation methods for protein processing
|
TW200938221A
(en)
|
2007-11-30 |
2009-09-16 |
Abbott Lab |
Protein formulations and methods of making same
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
SG10201503304RA
(en)
|
2007-12-27 |
2015-06-29 |
Baxter Int |
Cell culture processes
|
EP2799450A1
(en)
|
2007-12-31 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Antibodies to TNFalpha
|
EP2240595B2
(en)
|
2008-01-03 |
2019-07-24 |
Cornell Research Foundation, Inc. |
Glycosylated protein expression in prokaryotes
|
WO2009086550A1
(en)
|
2008-01-03 |
2009-07-09 |
Abbott Laboratories |
Predicting long-term efficacy of a compound in the treatment of psoriasis
|
JP5635912B2
(ja)
|
2008-01-15 |
2014-12-03 |
アッヴィ・インコーポレイテッド |
改善された哺乳動物発現ベクター及びその使用
|
NZ601913A
(en)
|
2008-01-15 |
2014-02-28 |
Abbott Gmbh & Co Kg |
Powdered protein compositions and methods of making same
|
EP2247310A4
(en)
|
2008-01-30 |
2012-06-27 |
Abbott Lab |
COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODY FRAGMENTS
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
JP2011514895A
(ja)
|
2008-02-29 |
2011-05-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
精製免疫グロブリン融合タンパク質およびその精製方法
|
CA2717614A1
(en)
|
2008-03-11 |
2009-09-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
CN102282173A
(zh)
|
2008-03-24 |
2011-12-14 |
艾博特生物技术有限公司 |
用于治疗骨丢失的方法和组合物
|
CA2719923A1
(en)
|
2008-04-08 |
2009-10-15 |
Amyris Biotechnologies, Inc. |
Expression of heterologous sequences
|
JP5624535B2
(ja)
|
2008-05-02 |
2014-11-12 |
シアトル ジェネティクス,インコーポレーテッド |
低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
|
WO2009135656A1
(en)
|
2008-05-06 |
2009-11-12 |
Lonza Biologics Plc. |
A method for the purification of antibodies using displacement chromatography
|
RU2010153580A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
US8318416B2
(en)
|
2008-08-08 |
2012-11-27 |
Biogen Idec Ma Inc. |
Nutrient monitoring and feedback control for increased bioproduct production
|
DK3604324T3
(da)
|
2008-08-14 |
2024-04-08 |
Genentech Inc |
Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
|
US20100069617A1
(en)
|
2008-09-12 |
2010-03-18 |
Ge Healthcare Bio-Sciences Ab |
Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
|
JP2012503656A
(ja)
|
2008-09-26 |
2012-02-09 |
エウレカ セラピューティクス,インコーポレイテッド |
変異体グリコシル化パターンを有する細胞株およびタンパク質
|
WO2010043703A1
(en)
|
2008-10-17 |
2010-04-22 |
Dsm Ip Assets B.V. |
Removal of host cell proteins
|
SG195577A1
(en)
|
2008-10-20 |
2013-12-30 |
Abbott Lab |
Viral inactivation during purification of antibodies
|
EP2346901A1
(en)
*
|
2008-10-20 |
2011-07-27 |
Abbott Laboratories |
Antibodies that bind to il-18 and methods of purifying the same
|
CN105111309A
(zh)
|
2008-10-20 |
2015-12-02 |
Abbvie公司 |
使用a蛋白亲和层析分离和纯化抗体
|
GB0821100D0
(en)
|
2008-11-18 |
2008-12-24 |
Hansa Medical Ab |
Antibodies
|
AU2009327435A1
(en)
|
2008-12-19 |
2010-06-24 |
Momenta Pharmaceuticals, Inc. |
Methods related to modified glycans
|
US8729241B2
(en)
|
2008-12-19 |
2014-05-20 |
Momenta Pharmaceuticals, Inc. |
Characterization of O-linked glycans
|
US8614297B2
(en)
|
2008-12-22 |
2013-12-24 |
Hoffmann-La Roche Inc. |
Anti-idiotype antibody against an antibody against the amyloid β peptide
|
JP5785098B2
(ja)
|
2009-01-08 |
2015-09-24 |
ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ |
単一ポリマー相系を用いる分離方法
|
SG173078A1
(en)
|
2009-01-22 |
2011-08-29 |
Momenta Pharmaceuticals Inc |
Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from cho cells
|
CA2752393C
(en)
|
2009-03-05 |
2020-01-14 |
Biogen Idec Ma Inc. |
Purification of immunoglobulins
|
EP2233499A1
(en)
|
2009-03-26 |
2010-09-29 |
CSL Behring AG |
Antibody composition with altered Fab sialylation
|
SI2420572T1
(sl)
|
2009-04-01 |
2015-10-30 |
Evec Incorporated |
Monoklonsko protitelo, ki je sposobno vezave na specifični diskontinuirani epitop, ki se pojavi pri regiji ad1 glikoproteina gb človeškega citomegalovirusa, in njegov antigen-vezavni fragment
|
EP2421892A1
(en)
|
2009-04-20 |
2012-02-29 |
Pfizer Inc. |
Control of protein glycosylation and compositions and methods relating thereto
|
JP5677411B2
(ja)
|
2009-04-29 |
2015-02-25 |
アッヴィ バイオテクノロジー リミテッド |
自動注入機器
|
US20120282654A1
(en)
|
2009-04-29 |
2012-11-08 |
Schering Corporation |
Antibody purification
|
CA2760185A1
(en)
|
2009-05-04 |
2010-11-11 |
Abbott Biotechnology Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha antibodies
|
US20120329709A1
(en)
|
2009-05-26 |
2012-12-27 |
Brian Edward Collins |
Production of glycoproteins
|
CA2763757A1
(en)
|
2009-05-28 |
2010-12-02 |
Boehringer Ingelheim International Gmbh |
Method for a rational cell culturing process
|
AU2010252230B2
(en)
|
2009-05-28 |
2013-07-04 |
Eth Zurich |
N-glycan core beta-galactosyltransferase and uses thereof
|
US20120277165A1
(en)
|
2009-06-05 |
2012-11-01 |
Collins Brian E |
Methods of modulating fucosylation of glycoproteins
|
PL2451936T3
(pl)
|
2009-07-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Sposób hodowli komórek eukariotycznych
|
EP2456789A1
(en)
|
2009-07-24 |
2012-05-30 |
F. Hoffmann-La Roche AG |
Optimizing the production of antibodies
|
US8945895B2
(en)
|
2009-07-31 |
2015-02-03 |
Baxter International Inc. |
Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
|
WO2011015926A1
(en)
|
2009-08-03 |
2011-02-10 |
Avesthagen Limited |
A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
LT2464725T
(lt)
|
2009-08-11 |
2020-06-10 |
F. Hoffmann-La Roche Ag |
Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
WO2011024025A1
(en)
|
2009-08-28 |
2011-03-03 |
Avesthagen Limited |
An erythropoietin analogue and a method thereof
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
US8470552B2
(en)
|
2009-10-12 |
2013-06-25 |
Keck Graduate Institute |
Strategy to reduce lactic acid production and control PH in animal cell culture
|
EP2325296A1
(en)
|
2009-11-20 |
2011-05-25 |
LEK Pharmaceuticals d.d. |
Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
|
WO2011065940A1
(en)
|
2009-11-24 |
2011-06-03 |
Biogen Idec Ma Inc. |
Method of supplementing culture media to prevent undesirable amino acid substitutions
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US20110136682A1
(en)
|
2009-12-04 |
2011-06-09 |
Momenta Pharmaceuticals, Inc. |
Antennary fucosylation in glycoproteins from cho cells
|
PL3715356T3
(pl)
|
2009-12-18 |
2024-03-11 |
Csl Limited |
Sposób oczyszczania polipeptydów
|
US20120014956A1
(en)
|
2010-02-02 |
2012-01-19 |
Hartmut Kupper |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
EP2531592A1
(en)
|
2010-02-04 |
2012-12-12 |
Vivalis |
Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
|
KR20120118065A
(ko)
|
2010-02-12 |
2012-10-25 |
디에스엠 아이피 어셋츠 비.브이. |
단일 단위체 항체 정제
|
EP2545066B1
(en)
|
2010-03-10 |
2017-09-20 |
F. Hoffmann-La Roche AG |
Method for purifying immunoglobulin solutions
|
US8981081B2
(en)
|
2010-03-12 |
2015-03-17 |
Purecircle Usa Inc. |
High-purity steviol glycosides
|
CN102869784A
(zh)
|
2010-04-07 |
2013-01-09 |
动量制药公司 |
高甘露糖聚糖
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
US20110262965A1
(en)
|
2010-04-23 |
2011-10-27 |
Life Technologies Corporation |
Cell culture medium comprising small peptides
|
PL3330370T3
(pl)
|
2010-04-26 |
2021-09-20 |
Novartis Ag |
Sposób hodowania komórek cho
|
JP6347949B2
(ja)
|
2010-04-26 |
2018-06-27 |
ノバルティス アーゲー |
改良型細胞培養培地
|
MX343604B
(es)
|
2010-05-28 |
2016-11-11 |
Genentech Inc |
Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.
|
ES2685607T3
(es)
|
2010-06-03 |
2018-10-10 |
Abbvie Biotechnology Ltd |
Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS)
|
US9428546B2
(en)
|
2010-07-30 |
2016-08-30 |
Pfizer Inc. |
Tandem purification of proteins
|
CN103080300B
(zh)
|
2010-08-05 |
2015-11-25 |
安姆根有限公司 |
增加细胞培养物的产率和活力的二肽
|
DE102010038990A1
(de)
|
2010-08-06 |
2012-02-09 |
Robert Bosch Gmbh |
Wellenlagervorrichtung für eine Handwerkzeugmaschine
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
CN103119448A
(zh)
|
2010-09-17 |
2013-05-22 |
Abbvie公司 |
用于生物过程操作的拉曼光谱
|
CA2810909A1
(en)
|
2010-09-20 |
2012-03-29 |
Abbvie Inc. |
Purification of antibodies using simulated moving bed chromatography
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
JP5888616B2
(ja)
*
|
2010-10-08 |
2016-03-22 |
カディラ・ヘルスケア・リミテッド |
組換えタンパク質の高レベル発現用の発現ベクター
|
SG10201508401TA
(en)
|
2010-10-11 |
2015-11-27 |
Abbvie Bahamas Ltd |
Processes for purification of proteins
|
CN103154243A
(zh)
|
2010-10-15 |
2013-06-12 |
日本化学研究株式会社 |
糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
|
EP2450375A1
(en)
|
2010-11-09 |
2012-05-09 |
Sandoz Gmbh |
Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
|
AU2011325974B2
(en)
|
2010-11-11 |
2016-10-27 |
Abbvie Biotechnology Ltd. |
Improved high concentration anti-TNFalpha antibody liquid formulations
|
WO2012068134A1
(en)
|
2010-11-15 |
2012-05-24 |
Biogen Idec Inc. |
Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
|
US20120149878A1
(en)
|
2010-12-08 |
2012-06-14 |
Gillespie Ronald |
Protein purification
|
EP2661448A4
(en)
|
2011-01-07 |
2015-09-16 |
Abbvie Inc |
ANTI-IL-12 / IL-23 ANTIBODIES AND USES THEREOF
|
TW201309330A
(zh)
|
2011-01-28 |
2013-03-01 |
Abbott Lab |
包含糖基化抗體之組合物及其用途
|
AR085302A1
(es)
|
2011-02-24 |
2013-09-18 |
Sanofi Sa |
Metodo de produccion de anticuerpos sialilados
|
CN109797138A
(zh)
|
2011-03-06 |
2019-05-24 |
默克雪兰诺有限公司 |
低岩藻糖细胞系及其应用
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
TWI743461B
(zh)
|
2011-03-28 |
2021-10-21 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
EP2511293A1
(en)
|
2011-04-13 |
2012-10-17 |
LEK Pharmaceuticals d.d. |
A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
|
WO2012145682A1
(en)
|
2011-04-21 |
2012-10-26 |
Amgen Inc. |
A method for culturing mammalian cells to improve recombinant protein production
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
CN105189735B
(zh)
|
2011-04-29 |
2019-04-12 |
拜康研究有限公司 |
在培养期间减少乳酸累积的方法和生产多肽的方法
|
CN104024423B
(zh)
|
2011-04-29 |
2017-03-15 |
拜康研究有限公司 |
用于降低抗体异质性的方法和产生其抗体的方法
|
KR20230006042A
(ko)
|
2011-04-29 |
2023-01-10 |
셀렉타 바이오사이언시즈, 인크. |
항체 반응을 감소시키기 위한 관용원성 합성 나노운반체
|
JP6236383B2
(ja)
|
2011-05-13 |
2017-11-22 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
トリスルフィド結合を防止および除去する方法
|
WO2013006461A1
(en)
|
2011-07-01 |
2013-01-10 |
Biogen Idec Ma Inc. |
Cholesterol-based media supplementals for cell culture
|
CA2952347A1
(en)
|
2011-07-01 |
2013-01-10 |
Amgen Inc. |
Mammalian cell culture
|
US10323081B2
(en)
|
2011-07-06 |
2019-06-18 |
Genmag A/S |
Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
|
US9475858B2
(en)
|
2011-07-08 |
2016-10-25 |
Momenta Pharmaceuticals, Inc. |
Cell culture process
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
WO2013013013A2
(en)
|
2011-07-21 |
2013-01-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for producing modified glycoproteins
|
BR112014003110A2
(pt)
|
2011-08-10 |
2018-10-09 |
Lab Francais Du Fractionnement |
composição, método para produção de uma população altamente galactosilada de anticorpos, células epiteliais de glândula mamária e mamífero não humano tramsgênico
|
US20130149300A1
(en)
|
2011-09-27 |
2013-06-13 |
Icon Genetics Gmbh |
MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
|
EP2773439A4
(en)
|
2011-10-31 |
2015-07-01 |
Merck Sharp & Dohme |
CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
|
SI3257564T1
(sl)
|
2011-11-02 |
2019-04-30 |
F. Hoffmann-La Roche Ag |
Izpiralna kromatografija s preobremenitvijo
|
ES2692539T3
(es)
|
2011-12-19 |
2018-12-04 |
The Rockefeller University |
Polipéptidos antiinflamatorios no sialilados
|
SG10201609982PA
(en)
|
2012-03-07 |
2017-01-27 |
Cadila Healthcare Ltd |
Pharmaceutical formulations of tnf-alpha anitbodies
|
SG10201701224UA
(en)
|
2012-03-12 |
2017-04-27 |
Merck Patent Gmbh |
Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
TW201348246A
(zh)
|
2012-05-21 |
2013-12-01 |
Abbvie Inc |
利用蛋白質a親和性層析之人類、人類化或嵌合抗體之新穎純化
|
US20140154270A1
(en)
|
2012-05-21 |
2014-06-05 |
Chen Wang |
Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
US20150158943A1
(en)
|
2012-06-01 |
2015-06-11 |
Momenta Pharmaceuticals, Inc. |
Methods related to adalimumab
|
JP2015519382A
(ja)
|
2012-06-12 |
2015-07-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
治療用抗体のための医薬処方物
|
WO2014018747A2
(en)
|
2012-07-26 |
2014-01-30 |
Momenta Pharmaceuticals, Inc. |
Glycoproteins with anti-inflammatory properties
|
KR102410763B1
(ko)
|
2012-08-17 |
2022-06-20 |
모르포시스 아게 |
복합체-특이적 항체 및 항체 단편 및 그의 용도
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
TW202042841A
(zh)
|
2012-09-07 |
2020-12-01 |
美商柯赫勒斯生物科學有限公司 |
阿達木單抗(adalimumab)之穩定水性調配物
|
US20150252108A1
(en)
|
2012-09-26 |
2015-09-10 |
Momenta Pharmaceuticals, Inc. |
Glycoprotein preparations
|
EP2931749B1
(fr)
|
2012-12-17 |
2019-04-24 |
Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
WO2014099636A1
(en)
|
2012-12-18 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Liquid formulations for an anti-tnf alpha antibody
|
ES2755181T3
(es)
|
2013-02-13 |
2020-04-21 |
Lab Francais Du Fractionnement |
Anticuerpos anti-TNF-alfa altamente galactosilados y usos de los mismos
|
WO2014134657A1
(en)
|
2013-03-08 |
2014-09-12 |
Sunyette Pty Ltd |
A cell expression system
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US20140271633A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Mammalian cell culture performance through surfactant supplementation of feed media
|
US8956830B2
(en)
|
2013-03-14 |
2015-02-17 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
US9677105B2
(en)
|
2013-03-14 |
2017-06-13 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
US20140271622A1
(en)
|
2013-03-14 |
2014-09-18 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
BR112015017307A2
(pt)
|
2013-03-14 |
2017-11-21 |
Abbvie Inc |
composições de espécies com baixa acidez e métodos para produção e uso das mesmas
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
TWI670279B
(zh)
|
2013-03-15 |
2019-09-01 |
美商艾爾德生物製藥股份有限公司 |
抗體純化及純度監測
|
CA2907140A1
(en)
|
2013-03-15 |
2014-09-25 |
Janssen Biotech, Inc. |
Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
|
EP3719122A1
(en)
|
2013-05-02 |
2020-10-07 |
Momenta Pharmaceuticals, Inc. |
Sialylated glycoproteins
|
KR101569783B1
(ko)
|
2013-06-05 |
2015-11-19 |
한화케미칼 주식회사 |
항체의 정제 방법
|
TWI596107B
(zh)
|
2013-06-25 |
2017-08-21 |
卡地拉保健有限公司 |
單株抗體之新穎純化方法
|
CN105431454A
(zh)
|
2013-07-06 |
2016-03-23 |
卡迪拉保健有限公司 |
用于生产单克隆抗体的改进方法
|
RU2662558C2
(ru)
|
2013-07-19 |
2018-07-26 |
Хексаль Аг |
Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
|
EP3027625B1
(en)
|
2013-07-31 |
2018-05-30 |
Merck Sharp & Dohme Corp. |
Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2016007764A1
(en)
|
2014-07-09 |
2016-01-14 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
|
WO2016022377A2
(en)
|
2014-08-05 |
2016-02-11 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
|